Aaron Viny

Assistant Professor of Medicine

Columbia University Irving Medical Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Aaron Viny is an Assistant Professor of Medicine at Columbia University Irving Medical Center in the United States. His recent research encompasses areas such as acute myeloid leukemia, chromatin organization in myelodysplastic syndrome, and germline predisposition for clonal hematopoiesis. His work contributes to understanding the molecular mechanisms and treatment targets within hematologic malignancies.

Articles (13)

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Collaborators (8)

Jeremy Shaw

University of Virginia

UNITED STATES

View details

Yue Yang

Northwestern University

UNITED STATES

View details

Assistant Professor

University of Tokyo

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Aaron Viny

Research Interests

Explore related searches

Contact this professor

About

Articles (13)

Acute myeloid leukemia stratifies as 2 clinically relevant sphingolipidomic subtypes

Chromatin organization in myelodysplastic syndrome

Germline predisposition for clonal hematopoiesis

Till SMARCA5 loss do nucleosomes part

BRD9 determines the cell fate of hematopoietic stem cells by regulating chromatin state

Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia

DNMT3A-Mutant Leukemia Cells Primed to “Fork It Over” under DNA Damage

Combinatorial genetics reveals the Dock1-Rac2 axis as a potential target for the treatment of NPM1;Cohesin mutated AML.

Subtype-specific 3D genome alteration in acute myeloid leukaemia

PU.1-Dependent Enhancer Inhibition Separates Tet2-Deficient Hematopoiesis from Malignant Transformation

Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia

Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation

Driver mutations in acute myeloid leukemia

Collaborators (8)

Jeremy Shaw

Yue Yang

George Vassiliou

Cyriac Kandoth

Bishal Paudel

Yu Luan

Tushar D. Bhagat

Tsukasa Shigehiro

Make your next move.